Works matching DE "TELAPREVIR"

Results: 203
    1
    2
    3
    4

    The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.

    Published in:
    Journal of Gastroenterology, 2015, v. 50, n. 3, p. 313, doi. 10.1007/s00535-014-0965-8
    By:
    • Oze, Tsugiko;
    • Hiramatsu, Naoki;
    • Yakushijin, Takayuki;
    • Yamada, Ryoko;
    • Harada, Naoki;
    • Morishita, Naoki;
    • Yamada, Akira;
    • Oshita, Masahide;
    • Kaneko, Akira;
    • Suzuki, Kunio;
    • Inui, Yoshiaki;
    • Tamura, Shinji;
    • Yoshihara, Harumasa;
    • Imai, Yasuharu;
    • Miyagi, Takuya;
    • Yoshida, Yuichi;
    • Tatsumi, Tomohide;
    • Kasahara, Akinori;
    • Hayashi, Norio;
    • Takehara, Tetsuo
    Publication type:
    Article
    5

    Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.

    Published in:
    Journal of Gastroenterology, 2014, v. 49, n. 12, p. 1548, doi. 10.1007/s00535-013-0924-9
    By:
    • Fujino, Hatsue;
    • Imamura, Michio;
    • Nagaoki, Yuko;
    • Kawakami, Yoshiiku;
    • Abe, Hiromi;
    • Hayes, C.;
    • Kan, Hiromi;
    • Fukuhara, Takayuki;
    • Kobayashi, Tomoki;
    • Masaki, Keiichi;
    • Ono, Atsushi;
    • Nakahara, Takashi;
    • Honda, Youji;
    • Naeshiro, Noriaki;
    • Urabe, Ayako;
    • Yokoyama, Satoe;
    • Miyaki, Daisuke;
    • Murakami, Eisuke;
    • Kawaoka, Tomokazu;
    • Hiraga, Nobuhiko
    Publication type:
    Article
    6

    Baseline factors and very early viral response (week 1) for predicting sustained virological response in telaprevir-based triple combination therapy for Japanese genotype 1b chronic hepatitis C patients: a multicenter study.

    Published in:
    Journal of Gastroenterology, 2014, v. 49, n. 11, p. 1485, doi. 10.1007/s00535-013-0918-7
    By:
    • Shimada, Noritomo;
    • Toyoda, Hidenori;
    • Tsubota, Akihito;
    • Ide, Tatsuya;
    • Takaguchi, Koichi;
    • Kato, Keizo;
    • Kondoh, Masaki;
    • Matsuyama, Kazuhiro;
    • Kumada, Takashi;
    • Sata, Michio
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18

    Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.

    Published in:
    Journal of Antimicrobial Chemotherapy (JAC), 2014, v. 69, n. 2, p. 483, doi. 10.1093/jac/dkt371
    By:
    • Furusyo, Norihiro;
    • Ogawa, Eiichi;
    • Murata, Masayuki;
    • Toyoda, Kazuhiro;
    • Ohnishi, Hachiro;
    • Eiraku, Kunimitsu;
    • Shimizu, Motohiro;
    • Harada, Yuji;
    • Mitsumoto, Fujiko;
    • Takayama, Koji;
    • Kainuma, Mosaburo;
    • Okada, Kyoko;
    • Hayashi, Jun
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28

    Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.

    Published in:
    Annals of Gastroenterology, 2017, v. 30, n. 3, p. 327, doi. 10.20524/aog.2017.0136
    By:
    • Mangia, Alessandra;
    • Foster, Graham R.;
    • Berg, Christoph P.;
    • Curescu, Manuela;
    • De Ledinghen, Victor;
    • Habersetzer, François;
    • Manolakopoulos, Spilios;
    • Negri, Elisa;
    • Papatheodoridis, George;
    • Ahlers, Silke;
    • Castillo, Marco;
    • Bakalos, Georgios;
    • Mauss, Stefan
    Publication type:
    Article
    29
    30
    31
    32

    Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy.

    Published in:
    PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0125080
    By:
    • Neukam, Karin;
    • Munteanu, Daniela I.;
    • Rivero-Juárez, Antonio;
    • Lutz, Thomas;
    • Fehr, Jan;
    • Mandorfer, Mattias;
    • Bhagani, Sanjay;
    • López-Cortés, Luis F.;
    • Haberl, Annette;
    • Stoeckle, Marcel;
    • Márquez, Manuel;
    • Scholten, Stefan;
    • de los Santos-Gil, Ignacio;
    • Mauss, Stefan;
    • Rivero, Antonio;
    • Collado, Antonio;
    • Delgado, Marcial;
    • Rockstroh, Juergen K.;
    • Pineda, Juan A.
    Publication type:
    Article
    33
    34

    Individualized Treatment of Genotype 1 Naïve Patients: An Italian Multicenter Field Practice Experience.

    Published in:
    PLoS ONE, 2014, v. 9, n. 10, p. 1, doi. 10.1371/journal.pone.0110284
    By:
    • Mangia, Alessandra;
    • Cenderello, Giovanni;
    • Orlandini, Alessandra;
    • Piazzolla, Valeria;
    • Picciotto, Antonio;
    • Zuin, Massimo;
    • Ciancio, Alessia;
    • Brancaccio, Giuseppina;
    • Forte, Paolo;
    • Carretta, Vito;
    • Zignego, Anna Linda;
    • Minerva, Nicola;
    • Brindicci, Gaetano;
    • Marignani, Massimo;
    • Baroni, Gianluca Svegliati;
    • Bertino, Gaetano;
    • Cuccorese, Giuseppe;
    • Mottola, Leonardo;
    • Ripoli, Maria;
    • Pirisi, Mario
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment.

    Published in:
    Experimental & Therapeutic Medicine, 2016, v. 12, n. 5, p. 3353, doi. 10.3892/etm.2016.3785
    By:
    • MITSUYUKI SUZUKI;
    • TORU ISHIKAWA;
    • AI SAKUMA;
    • SATOSHI ABE;
    • HIROKO ABE;
    • FUJIKO KOYAMA;
    • TOMOMI NAKANO;
    • AYA UEKI;
    • HIROHITO NOGUCHI;
    • ERINA HASEGAWA;
    • SHIORI YAMAGATA;
    • MIKI KOBAYASHI;
    • KAZUTAKA OHASHI;
    • HIROSHI HIROSAWA;
    • TAKAKO FUKAZAWA;
    • YUKA MARUYAMA;
    • TOSHIAKI YOSHIDA
    Publication type:
    Article
    45
    46
    47
    48
    49
    50